Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease~* Have a history of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Have Diabetes Mellitus~* Have a self-reported change in body weight \>5 kg within 3 months prior to screening~* Have obesity induced by other endocrinological disorders~* Have had a history of chronic or acute pancreatitis~* Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Have any lifetime history of a suicide attempt~* Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 Milligrams (mg) Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo SC QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).